Ferric carboxymaltose vs. ferrous sulfate for the treatment of anemia in advanced chronic kidney disease: an observational retrospective study and cost analysis

Ferric carboxymaltose vs. ferrous sulfate for the treatment of anemia in advanced chronic kidney disease: an observational retrospective study and cost analysis

Abstract In non-dialysis-dependent chronic kidney disease (NDD-CKD), erythropoiesis-stimulating agents (ESAs) and iron supplementation are essential for anemia management. Ferric carboxymaltose (FCM) is a relatively novel intravenous iron formulation used in different clinical settings, although sca...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Luigi Cirillo, Chiara Somma, Marco Allinovi, Alfredo Bagalà, Giuseppe Ferro, Elio Di Marcantonio, Stefania Bellelli, Lorenzo Antonio Dallari, Piercarlo Ballo, Pietro Claudio Dattolo
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/8bf66b7aa4f642edb1678b2fafad36a4
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares